Ponatinib Hydrochloride

盐酸泊那替尼

Report date: 2026/03/19 20:00:18
NME

Base Information

Drug NamePonatinib Hydrochloride
Drug Alias Name帕纳替尼泊那替尼珀那替尼普纳替尼盐酸普纳替尼 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsTEK receptor tyrosine kinase antagonistsTyrosine-protein kinase SRC inhibitors +[9] 
TargetsStem cell growth factor receptorFibroblast growth factor receptorsTyrosine-protein kinase SRC +[9] 
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Solid tumoursPhiladelphia Chromosome +[23] 
Global Approved IndicationsLeukemia, Myelogenous, ChronicPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Approved Indications in ChinaLeukemia, Myelogenous, ChronicPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Original Approved Country/TerritoryUnited States
Original Approved Date2012/12/14
Country/TerritoryCzechiaBelgiumBulgaria +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAriad
China Registration ClassN/A

Develop Information

Active CompaniesPatheon Inc-Toronto Region OperationsOtsuka Holdings Co LtdIncyte Corp +[11] 
Inactive CompaniesDana-Farber Cancer InstituteTakeda (China) International Trading Co LtdNational Institutes Of Health Clinical Center (Cc) +[12] 
Active IndicationsSolid tumoursPhiladelphia ChromosomeLymphoma +[11] 
Inactive IndicationsMedullary thyroid cancer (MTC)Small Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[12] 

Other Information

ATC CodeL01EA05
Related LinksWikipediaDrugBankKEGG